Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

286 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
Konecny GE, Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, Ray-Coquard I, Aghajanian C, Coleman RL, O'Malley DM, Leary A, Chen LM, Provencher D, Ma L, Brenton JD, Castro C, Green M, Simmons AD, Beltman J, Harding T, Lin KK, Goble S, Maloney L, Kristeleit RS, McNeish IA, Swisher EM, Xiao JJ. Konecny GE, et al. Among authors: provencher d. Gynecol Oncol. 2021 Jun;161(3):668-675. doi: 10.1016/j.ygyno.2021.03.015. Epub 2021 Mar 19. Gynecol Oncol. 2021. PMID: 33752918 Free PMC article.
RETIRED: Progesterone-only and non-hormonal contraception in the breast cancer survivor: Joint Review and Committee Opinion of the Society of Obstetricians and Gynaecologists of Canada and the Society of Gynecologic Oncologists of Canada.
McNaught J, Reid RL; SOGC/GOC JOINT AD HOC COMMITTEE ON BREAST CANCER. McNaught J, et al. J Obstet Gynaecol Can. 2006 Jul;28(7):616-626. doi: 10.1016/S1701-2163(16)32195-8. J Obstet Gynaecol Can. 2006. PMID: 16924781 English, French. No abstract available.
Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care.
Fung-Kee-Fung M, Provencher D, Rosen B, Hoskins P, Rambout L, Oliver T, Gotlieb W, Covens A; IP Chemotherapy Working Group/Society of Gynecologic Oncologists of Canada. Fung-Kee-Fung M, et al. Among authors: provencher d. Gynecol Oncol. 2007 Jun;105(3):747-56. doi: 10.1016/j.ygyno.2007.02.015. Epub 2007 Mar 21. Gynecol Oncol. 2007. PMID: 17368522
Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.
Oza AM, Eisenhauer EA, Elit L, Cutz JC, Sakurada A, Tsao MS, Hoskins PJ, Biagi J, Ghatage P, Mazurka J, Provencher D, Dore N, Dancey J, Fyles A. Oza AM, et al. Among authors: provencher d. J Clin Oncol. 2008 Sep 10;26(26):4319-25. doi: 10.1200/JCO.2007.15.8808. Epub 2008 Jun 30. J Clin Oncol. 2008. PMID: 18591547 Clinical Trial.
An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21 days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer.
Rose PG, Monk BJ, Provencher D, Hartney J, Legenne P, Lane S. Rose PG, et al. Among authors: provencher d. Gynecol Oncol. 2011 Jan;120(1):38-42. doi: 10.1016/j.ygyno.2010.10.011. Epub 2010 Nov 5. Gynecol Oncol. 2011. PMID: 21055798 Clinical Trial.
286 results